Stockscreener 앱 받기
9.23
4.15%
-0.40
시간 외 거래:
9.22
-0.010
-0.11%
전일 마감가:
$9.63
열려 있는:
$9.54
하루 거래량:
46,483
Relative Volume:
0.69
시가총액:
$81.16M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-461.50
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
-0.86%
1개월 성능:
-27.89%
6개월 성능:
-43.16%
1년 성능:
-60.22%
1일 변동 폭
$9.14
$9.73
1주일 범위
$8.92
$10.12
52주 변동 폭
$7.179
$30.60
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
9.23 | 81.16M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Manila Times
Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan
Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com Nigeria
Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com
JP Morgan downgrades Seres Therapeutics Inc (MCRB) rating to an Underweight - knoxdaily.com
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023 - marketscreener.com
Upcoming Stock Splits This Week (April 21 to April 25) – Stay Invested - The Globe and Mail
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts
MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa
MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com
Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com
Seres Therapeutics Approves Reverse Stock Split Plan - TipRanks
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World
Strategic Power Move: Kymera Lands M&A Expert to Accelerate Drug Development Deals - Stock Titan
MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia
MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire
5 Best Microbiome Companies (May 2025) - Securities.io
Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World
Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat
Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World
Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.
Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World
The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey
Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic? - Yahoo Finance
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):